Stability of an extemporaneous oral liquid aprepitant formulation

[1]  Karen C. Thompson,et al.  Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant , 2007, International journal of nanomedicine.

[2]  A. Favero,et al.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Kris,et al.  Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy , 2005, Supportive Care in Cancer.

[4]  F. Roila,et al.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Pearson,et al.  Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. , 2003, European journal of cancer.

[6]  K. Horgan,et al.  Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.

[7]  D. Osoba,et al.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Perez,et al.  ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  A. Favero,et al.  Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the Perugia Consensus Conference , 1998 .

[10]  A. Stewart.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Verweij,et al.  Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.

[12]  P. Butow,et al.  On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  K. Flora,et al.  Stability studies: five years later. , 1988, American journal of hospital pharmacy.

[14]  L. Trissel.  Avoiding common flaws in stability and compatibility studies of injectable drugs. , 1983, American journal of hospital pharmacy.

[15]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.